Drägerwerk reports weaker third-quarter EBIT. Drägerwerk stock falls 1.77 percent

Published on 10/20/2026 at 11:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orders rose 8.2 percent to EUR 926 million. Drägerwerk stock costs EUR 94.05 on October 20, 2026 versus EUR 95.80 at the Xetra close.

Margins face the next test

Preliminary third-quarter EBIT reached EUR 48 million on October 14, 2026.
mwb research kept its EUR 135.00 target on October 15, 2026.
Drägerwerk stock trades at EUR 94.05 at 11:04 a.m. CEST at Lang & Schwarz on October 20, 2026, 1.77 percent below the Xetra close of October 19, 2026.
The full third-quarter report is scheduled for October 29, 2026.

Moderne Intensivstation mit Beatmungsgerät und Patientenmonitoring in klinischer Umgebung — Drägerwerk AG & Co. KGaA zeigt moderne Intensivstation mit Beatmungsgeräten und Patientenmonitoring DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) reported preliminary third-quarter EBIT of EUR 48 million on October 14, 2026, down from EUR 56.70 million a year earlier. The stock was trading at EUR 94.05 at Lang & Schwarz at 11:04 a.m. CEST on October 20, 2026, 1.77 percent below the Xetra close of October 19, 2026 at EUR 95.80. The release pointed to higher functional costs despite tariff refunds.

Quarterly figures expose margin pressure

According to Deutsche Börse, third-quarter revenue rose 2.10 percent to EUR 851 million, while the EBIT margin fell to 5.60 percent from 6.80 percent in the third quarter of 2025. The EBIT included EUR 20.10 million in tariff refunds, making the margin quality a central issue for investors.

Orders provided a counterweight. Third-quarter order intake rose 8.20 percent to EUR 926 million, with Safety Technology orders up 20.20 percent to EUR 452 million. Medical Technology orders fell 3.00 percent on a currency-adjusted basis to EUR 474 million.

What does the order growth mean?

The order data support Drägerwerk's full-year outlook, but the quarterly margin still trails the target. For the first nine months of 2026, revenue rose 5.30 percent to EUR 2.454 billion and EBIT increased to EUR 112 million from EUR 77.10 million a year earlier. The nine-month EBIT margin was 4.60 percent, below the full-year target range of 6.00 to 8.00 percent.

Three dated signals for the stock

On October 14, 2026, Drägerwerk published preliminary third-quarter figures with EUR 48 million EBIT. On October 15, 2026, FinanzNachrichten reported that mwb research retained a EUR 135.00 price target and a Buy rating. On October 20, 2026, the Lang & Schwarz quote stood at EUR 94.05 during trading.

Two dates set the next test

Drägerwerk plans to publish its full third-quarter report on October 29, 2026. The company is also scheduled to hold a Capital Markets Day on November 18, 2026, according to mwb research. These dates should clarify how quickly the company can convert stronger orders into margin expansion.

Stock stays below its recent range

The price sits within the 52-week range of EUR 66.00 to EUR 125.40 as of October 20, 2026. Drägerwerk describes its business as medical and safety technology serving hospitals, emergency services, industry and public-sector customers, with 2025 revenue of EUR 3.5 billion on its investor-relations page.

Drägerwerk was trading at EUR 94.05 at Lang & Schwarz on October 20, 2026 at 11:04 a.m. CEST, 1.77 percent below the Xetra close of October 19, 2026 at EUR 95.80. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.